Meropenem Fresenius Kabi (Meropenem Trihydrate)

Meropenem, the active ingredient in Meropenem Fresenius Kabi, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats serious bacterial infections such as intra‑abdominal, urinary tract, meningitis, skin and soft‑tissue infections, and sepsis in hospitalized patients.

GNH USA supplies Meropenem Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used for serious infections caused by susceptible bacteria.

- Complicated intra‑abdominal infections: provides bactericidal activity against the mixed flora involved, aiding infection resolution. - Complicated urinary tract infections: eradicates resistant Gram‑negative pathogens, helping to clear the urinary system. - Bacterial meningitis: penetrates the cerebrospinal fluid to eliminate causative organisms. - Skin and soft tissue infections: treats severe infections caused by resistant organisms. - Sepsis: offers rapid bacterial killing in systemic infections, supporting hemodynamic recovery.

Adverse reactions may occur with any antibiotic therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient and usually resolves. - Rash: erythematous skin eruption. - Infusion site phlebitis: pain or redness at IV site. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disease. - Clostridioides difficile colitis: severe diarrhea due to gut flora disruption. - Anaphylaxis: acute hypersensitivity reaction requiring emergency care. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: acute kidney injury in susceptible individuals. - Hypersensitivity reactions: including Stevens‑Johnson syndrome.

Careful assessment and monitoring are required before and during therapy.

- Renal function: adjust dose in patients with impaired renal clearance. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or other beta‑lactams. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Concomitant valproic acid: monitor for decreased seizure control. - Age: safety not established in neonates; use with caution in pediatric patients. - Store below 25°C: keep in the original pack, protect from moisture and light.

Meropenem may interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: reduces meropenem plasma levels, potentially precipitating seizures. - Warfarin: may increase INR and bleeding risk; monitor coagulation parameters. - Aminoglycosides: additive nephrotoxicity; avoid concurrent high‑dose use.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - Bacteriostatic antibiotics (e.g., chloramphenicol, tetracyclines): possible antagonism; assess clinical response. - Other anticonvulsants: monitor seizure control and drug levels.